Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma Patients
The American Surgeon™ · 2024
DOI: 10.1177/00031348241241620 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Surgeon™, 2024. Verfasst von Tarendeep Thind und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Enoxaparin, Wounds and Injuries, Anticoagulants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Introduction
Patients admitted after traumatic injuries are at high risk for developing venous thromboembolism (VTE). Low-molecular-weight heparin (LMWH) is commonly used to prevent VTE in this patient population; however, the optimal dosing strategy has yet to be determined. To address this question, a fixed-dosing strategy of LMWH was compared to a weight-based dosing strategy of LMWH for VTE prophylaxis.
Methods
A retrospective, pre-post implementation cohort study compared a fixed vs a weight-based dosing strategy of LMWH for VTE prophylaxis. Patients admitted to our level 1 trauma center were included if they had an estimated glomerular filtration rate >30 mL/min/1.73 m 2 , received at least 3 doses of LMWH, and had an appropriately drawn anti-Xa level on their initial dosing regimen. Patients in the pre-cohort received 30 mg LMWH subcutaneously twice daily as the initial dosing regimen. Patients in the post-cohort received .5 mg/kg (max 60 mg) LMWH subcutaneously every 12 h as the initial dosing regimen. A goal anti-Xa of .2-.4 IU/mL was targeted for prophylaxis.
Results
There were 817 patients in the fixed-dosing group (FDG) and 874 patients in the weight-based dosing group (WBDG). In the FDG, 42.8% of the patients achieved the goal initial anti-Xa level, with 54.1% and 3.1% reaching sub- and supratherapeutic doses, respectively. In the WBDG, 66.5% of patients reached goal initial anti-Xa levels, with 23.5% and 10.1% at sub- and supratherapeutic levels. The distribution of dose ranges was significantly different between the dosing strategies ( P-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- Department of Surgery, Division of Trauma and Acute Care Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- Department of Health Policy and Management, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
ORCID-Profile: Avi Bhavaraju
Zitieren
APA
Thind, T., Heye, T., Henson, C., Reif, R., Jensen, H. K., Kalkwarf, K. J., Bhavaraju, A., Robertson, R., & Jenkins, A. (2024). Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma Patients. The American Surgeon™. https://doi.org/10.1177/00031348241241620
Vancouver
Thind T, Heye T, Henson C, Reif R, Jensen HK, Kalkwarf KJ, et al. Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma Patients. The American Surgeon™. 2024. doi:10.1177/00031348241241620
BibTeX
@article{Thind2024,
author = {Thind, Tarendeep and Heye, Thomas and Henson, Curran and Reif, Rebecca and Jensen, Hanna K and Kalkwarf, Kyle J and Bhavaraju, Avi and Robertson, Ronald and Jenkins, Allison},
title = {Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma Patients},
journal = {The American Surgeon™},
year = {2024},
doi = {10.1177/00031348241241620}
}
EUVIMED